Skip to main content
Which to use in #EGPA? #Mepolizumab IL5i vs Benralizumab = monoclonal Ab binding to IL5Ralpha. Noninferiority RCT - both

Janet Pope

2 years 11 months ago
Which to use in #EGPA? #Mepolizumab IL5i vs Benralizumab = monoclonal Ab binding to IL5Ralpha. Noninferiority RCT - both are similar. Is more Impt ? IL5 drug vs #Rituximab or #Cyclo for severe Eosinoph granuloma todos w polyangiitis 🤷 #ACR23 ⁦@RheumNow⁩ ⁦@ACRheum⁩ https://t.co/zyZeHHSsck
Contributing Factors for Difficult-to-Treat RA using Natural Language Processing (NLP): joint erosions (OR 2.97 CI95% [

Dr. Antoni Chan

2 years 11 months ago
Contributing Factors for Difficult-to-Treat RA using Natural Language Processing (NLP): joint erosions (OR 2.97 CI95% [2.17; 4.08], p< 0.001) , higher disease activity (median DAS28 3.16 vs 2.89) associated with D2T, Bergier Abst#0383 #ACR23 @RheumNow https://t.co/KARxoa2Z7H
COVID boosters in RA patients:
getting the job done (versus healthy controls, irrespective of non-withheld DMARDs exclud

David Liew drdavidliew

2 years 11 months ago
COVID boosters in RA patients: getting the job done (versus healthy controls, irrespective of non-withheld DMARDs excluding ritux) @UChicagoMed #ACR23 ABST0416 @RheumNow https://t.co/HVRjC4dauw
I’m not TYK’ed! Another TYK2 #TAK-279 in #PsA RCT. Yup it works in ballpark of other PsA #Rx. #PASI75 45.7%. No obvi

Janet Pope

2 years 11 months ago
I’m not TYK’ed! Another TYK2 #TAK-279 in #PsA RCT. Yup it works in ballpark of other PsA #Rx. #PASI75 45.7%. No obvious dose response w 15 and 30 mg daily but more #acne at higher dose. #ACR23 @ACRheum @RheumNow poster L12 Where to use vs #Deucravitinib? Too early to say as Ph2 https://t.co/nMkgOlUf6s
Does knowing ischemic stroke subtypes among SLE patients matter?
This study by Hopia et al 👉54% of ischemic strokes

sheila

2 years 11 months ago
Does knowing ischemic stroke subtypes among SLE patients matter? This study by Hopia et al 👉54% of ischemic strokes in 56 SLE pts were APS/aPL & cardioembolic origin (accdg to TOAST) & +assoc with STAT4 gene. #ACR23 ABST0579 @RheumNow https://t.co/Ut8QPpQNQp
Can a picture tell a RA swollen joint?
(would be super useful for telehealth/remote monitor if so)

It's not prime time

David Liew drdavidliew

2 years 11 months ago
Can a picture tell a RA swollen joint? (would be super useful for telehealth/remote monitor if so) It's not prime time yet, but following with interest: using photos to pick up on skin folds/joint swelling Fascinating, but let's see it vs MRI, clinical #ACR23 ABST0402 @RheumNow https://t.co/TFKiD5J4c8
We gotta do better! Reproductive health counseling is poorly done- only a third rheumatologists surveyed ask pts about r

TheDaoIndex KDAO2011

2 years 11 months ago
We gotta do better! Reproductive health counseling is poorly done- only a third rheumatologists surveyed ask pts about reproductive health: sexual activity, pregnancy desire, contraception. Abstr#0162 @_michgarcia @rheumnow #ACR23 https://t.co/r9tewu2I9N
Smartwatches to measures axSpA activity?
Upadacitinib use in axSpA INCREASED physical activity based on a wearable medic

Robert B Chao, MD

2 years 11 months ago
Smartwatches to measures axSpA activity? Upadacitinib use in axSpA INCREASED physical activity based on a wearable medical device step count, especially in those who were originally sedentary. @RheumNow #ACR23 Abs#0530 #ACRbest https://t.co/oOFiQwMFZ6
SLE pts with +aCL IgG/IgM and LA had higher risk of developing atherosclerotic CVD accdg to this prospective study by Di

sheila

2 years 11 months ago
SLE pts with +aCL IgG/IgM and LA had higher risk of developing atherosclerotic CVD accdg to this prospective study by Ding et al. . . . 🧐Again, SLE pts have ⬆️CV risk so always risk stratify and intervene early. #ACR23 ABST0552 @RheumNow https://t.co/QhttQZzp8G
Year in Review by Dr. P Seo

NORD-STAR trial:
⭐️Abatacept or Certolizumab >> Tociluzumab > triple therap

Meral K. El Ramahi, MD MeralElRamahiMD

2 years 11 months ago
Year in Review by Dr. P Seo NORD-STAR trial: ⭐️Abatacept or Certolizumab >> Tociluzumab > triple therapy in tx of 812 early RA patients based on clinical & radiographic results ➡️tx-naive, all got MTX ➡️mod-sev dz activity ➡️randomized to 48 wks therapy #ACR23 @RheumNow https://t.co/vy2uYuyOse
Interesting question... but feels like some time related bias or perhaps confounding?

Seems implausible that MTX &

Mike Putman EBRheum

2 years 11 months ago
Interesting question... but feels like some time related bias or perhaps confounding? Seems implausible that MTX & biologic would be protective for PsO & harmful for PsA @RheumNow #ACR23 Abstr 0498 https://t.co/pSRoLHRTAm
NAFLD a real issue in RA
Does DMARD choice matter?

National Taiwanese data
newly dx RA n=41791

HCQ reduced NAFLD risk:

David Liew drdavidliew

2 years 11 months ago
NAFLD a real issue in RA Does DMARD choice matter? National Taiwanese data newly dx RA n=41791 HCQ reduced NAFLD risk: adjHR 0.75 (other RF: obesity, NSAIDs, even low-dose PNL; but not DM, MTX) Can HCQ improve liver health in RA? Authors: ?adiponectin #ACR23 ABST0396 @RheumNow https://t.co/9VMJpImFKs
C-VIEW study on certolizumab use in preventing anterior uveitis in high risk pts with axSpA.
All pts were B27+ w/ at lea

Robert B Chao, MD

2 years 11 months ago
C-VIEW study on certolizumab use in preventing anterior uveitis in high risk pts with axSpA. All pts were B27+ w/ at least one episode of anterior uveitis Uveitis flares lower in certolizumab group compared to non-bDMARD use @RheumNow #ACR23 Abs#0524 https://t.co/CfnhzStBMv
This study by Munoz-Grajales et al show that the analyte S100A8/A9 (highest AUC) was able to differentiate between SLE p

sheila

2 years 11 months ago
This study by Munoz-Grajales et al show that the analyte S100A8/A9 (highest AUC) was able to differentiate between SLE pts with cognitive impairment and those without. . . . Interesting findings. More data needed to confirm and explain why it is so. #ACR23 ABST0558 @RheumNow https://t.co/LcF6s2qgNr
PROs are useful for tracking RA disease activity over time outside of the clinic setting for patients initiating new tre

Dr. Antoni Chan

2 years 11 months ago
PROs are useful for tracking RA disease activity over time outside of the clinic setting for patients initiating new treatments without clinician-derived measures. Correlations in follow-up CDAI and PROs were 0.38 – 0.56, Nowell Abst#0380 #ACR23 @RheumNow https://t.co/LepCZ7sPY8 https://t.co/UYcZzIFEsx
×